Because elevated FBG is associated with increased risk for Type 2 diabetes (T2D), cardiovascular associated mortality (CAM), adverse pregnancy outcomes, heart disease, brain atrophy, and several types of cancer [18–31], G6PC2 inhibitors that lower FBG could have multiple therapeutic benefits. This evidence concerns the gene G6PC2 and type 2 diabetes mellitus.